Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | ELANE | P08246 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | PPARA | Q07869 | 4/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.40 |
| ▸ | HTR2A | P28223 | 2/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 2/20 | 0.39 |
| ▸ | PPARG | P37231 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4753578 | 0.92 | ELANE (0.57) | HPGDELANECYP1A2CYP2C19MEN1 | |
| Ethane SCHEMBL5531806 | 0.81 | MIF (0.50) | ELANECYP1A2CYP2C19MEN1KMT2A | |
| SCHEMBL3004950 | 0.80 | ELANE (0.49) | ELANECYP1A2CYP2C19MEN1KMT2A | |
| SCHEMBL4185924 | 0.80 | ELANE (0.66) | HPGDELANECYP1A2CYP2C19MEN1 | |
| SCHEMBL6930564 | 0.79 | POLB (0.40) | ELANEMAPTALDH1A1USP2NPSR1 | |
| Dobesilic Acid SCHEMBL11657182 | 0.79 | POLB (0.46) | HPGDMAPTALDH1A1RAB9AUSP2 | |
| SCHEMBL28175516 | 0.79 | SMN1; SMN2 (0.60) | CYP1A2CYP2C19MEN1KMT2APPARA | |
| SCHEMBL30893497 | 0.79 | MEN1 (0.37) | HPGDCYP1A2CYP2C19MEN1KMT2A | |
| SCHEMBL11538324 | 0.78 | ALDH1A3 (0.52) | HPGDELANEKMT2AMAPTALDH1A1 | |
| SCHEMBL6698370 | 0.78 | CYP1A2 (0.54) | HPGDELANECYP1A2CYP2C19PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012090225-A2 | NOVEL COCRYSTALS / MOLECULAR SALTS OF METFORMIN WITH OLEOYLETHANOLAMIDE AS AN EFFECTIVE ANTI-DIABETIC + ANTI- OBESITY AGENT | NUTRACRYST THERAPEUTICS PRIVATE LIMITED (IN) | 2012-07-05 | — | — | WO | claimed |
| WO-2025085109-A2 | METHODS OF PREVENTING POST-TRAUMATIC OSTEOARTHRITIS USING METFORMIN | THE TRUSTEES OF INDIANA UNIVERSITY (US) | 2025-04-24 | — | — | WO | disclosed |
| CN-104789649-A | Soybean event 127 and methods related thereto | BASF AGROCHEMICAL PRODUCTS BV | 2015-07-22 | — | — | CN | disclosed |
| EP-2109447-B1 | N, N- DIMETHYL IMIDODICARBONIMIDIC DIAMIDE ACETATE, METHOD FOR PRODUCING THE SAME AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | HANALL BIOPHARMA CO LTD (KR) | 2015-06-10 | — | — | EP | disclosed |
| CN-103834675-A | Herbicide-resistant ahas-mutants and methods of use | BASF AGROCHEMICAL PRODUCTS BV | 2014-06-04 | — | — | CN | disclosed |
| CN-102216453-B | Herbicide-resistant AHAS-mutants and methods of use | BASF AGROCHEMICAL PRODUCTS BV | 2014-02-05 | — | — | CN | disclosed |
| US-8541474-B2 | N,N-dimethyl imidodicarbonimidic diamide acetate, method for producing the same and pharmaceutical compositions comprising the same | HANALL BIOPHARMA CO., LTD. (KR) | 2013-09-24 | — | — | US | disclosed |
| WO-2012090225-A2 | NOVEL COCRYSTALS / MOLECULAR SALTS OF METFORMIN WITH OLEOYLETHANOLAMIDE AS AN EFFECTIVE ANTI-DIABETIC + ANTI- OBESITY AGENT | NUTRACRYST THERAPEUTICS PRIVATE LIMITED (IN) | 2012-07-05 | — | — | WO | disclosed |
| US-20120010287-A1 | N, N -DIMETHYL IMIDODICARBONIMIDIC DIAMIDE ACETATE, METHOD FOR PRODUCING THE SAME AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | HANNAL BIOPHARMA CO., LTD. (KR) | 2012-01-12 | — | — | US | disclosed |
| US-8058312-B2 | N, N-dimethyl imidodicarbonimidic diamide acetate, method for producing the same and pharmaceutical compositions comprising the same | HANALL BIOPHARMA CO., LTD. (KR) | 2011-11-15 | — | — | US | disclosed |
| WO-2008093984-A1 | N, N- DIMETHYL IMIDODICARBONIMIDIC DIAMIDE ACETATE, METHOD FOR PRODUCING THE SAME AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | HANALL PHARMACEUTICAL COMPANY. LTD (KR) | 2008-08-07 | — | — | WO | disclosed |
| EP-1372660-A2 | A COMBINATION OF FBPASE INHIBITORS AND ANTIDIABETIC AGENTS USEFUL FOR THE TREATMENT OF DIABETES | Metabasis Therapeutics, Inc. (US) | 2004-01-02 | — | — | EP | disclosed |
| US-20030073728-A1 | Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes | METABASIS THERAPEUTICS, INC. | 2003-04-17 | — | — | US | disclosed |
| WO-2002003978-A2 | A COMBINATION OF FBPase INHIBITORS AND ANTIDIABETIC AGENTS USEFUL FOR THE TREATMENT OF DIABETES | METABASIS THERAPEUTICS, INC. (US) | 2002-01-17 | — | — | WO | disclosed |
| EP-1039890-A4 | NOVEL SALTS OF METFORMIN AND METHOD | BRISTOL MYERS SQUIBB CO (US) | 2001-04-04 | — | — | EP | disclosed |
| EP-1039890-A1 | NOVEL SALTS OF METFORMIN AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-10-04 | — | — | EP | disclosed |
| CN-1248916-A | Use of FXR, PPAR 'alpha' and LXR 'alpha' activators to restore barrier function, promote epidermal differentiation and inhibit proliferation | UNIV CALIFORNIA (US) | 2000-03-29 | — | — | CN | disclosed |
| US-6031004-A | METFORMIN (2:1) FUMARATE AND METFORMIN (2:1) SUCCINATE; ANTIDIABETIC AND HYPOGLYCEMIC AGENTS; IMPROVED HANDLING, I.E. LOWER HYGROSCOPICITY, FREE-FLOWING, REDUCED COMPACTION SUSCEPTIBIITY, CORROSION RESISTANCE; IMPROVED TASTE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-02-29 | — | — | US | disclosed |
| WO-1999029314-A1 | NOVEL SALTS OF METFORMIN AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-06-17 | — | — | WO | disclosed |
| US-4118583-A | ANTICOAGULANT, ANTICHOLINERGIC AGENTS | LABORATORIES OM SOCIETE ANONYME (CH) | 1978-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073728-A1 | Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes | FBP1, ALDOA, G6PC1 | HPGD 1298/4885ELANE 3041/4885CYP1A2 3970/4885 |
| US-20120010287-A1 | N, N -DIMETHYL IMIDODICARBONIMIDIC DIAMIDE ACETATE, METHOD FOR PRODUCING THE SAME AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | TP53, TNNC1, TNNI3 | HPGD 1235/4885ELANE 3917/4885CYP1A2 3213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.